Orthofix Medical Inc.(OFIX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,209 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
OFIX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Orthofix Medical Inc. (OFIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OFIX at 38.2/100 on a 32-signal composite quality model, placing it at rank #2,209 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (19.7) and free cash flow (21.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Orthofix Medical Inc. reports quarterly revenue of $210.9M, net income of $-15.8M, an operating margin of -3.9%. Top institutional holders of OFIX by reported 13-F value include Engine Capital Management, Juniper Investment Company, Rubric Capital Management, based on the most recent SEC filings. OFIX trades on the Nasdaq exchange and files with the SEC under CIK 884624. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OFIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Orthofix Medical Inc. directly from SEC EDGAR. Orthofix Medical Inc.'s 13F Pro composite quality score has ranged between 28 and 54 since 2021, currently 38.2 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$210.9M
Net Income
Q2 2026
$-15.8M
Free Cash Flow
Q2 2026
$-18.9M
Operating Margin
Q2 2026
-3.9%
ROIC
Q2 2026
-5.0%
D/E Ratio
Q2 2026
0.52
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+2.9% YoYNet Income
+26.8% YoYOperating Income
+3.8% YoYEPS (Diluted)
+29.4% YoYTotal Assets
-4.8% YoYTotal Debt
+0.2% YoYOp. Cash Flow
+29.3% YoYFree Cash Flow
+85.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $822.3M +2.9% | $799.5M +7.1% | $746.6M +62.1% | $460.7M -0.8% | $464.5M +14.2% | $406.6M |
| Net Income | $-92.2M +26.8% | $-126.0M +16.8% | $-151.4M -666.6% | $-19.7M +48.5% | $-38.4M -1624.8% | $2.5M |
| Operating Income | $-81.4M +3.8% | $-84.6M +39.2% | $-139.1M -948.5% | $-13.3M -59.6% | $-8.3M -32.7% | $-6.3M |
| EPS (Diluted) | $-2.33 +29.4% | $-3.30 +19.9% | $-4.12 -320.4% | $-0.98 +49.7% | $-1.95 -1600.0% | $0.13 |
| Total Assets | $850.6M -4.8% | $893.3M -3.5% | $925.3M +101.8% | $458.6M -3.8% | $476.6M -9.4% | $525.9M |
| Total Debt | $157.4M +0.2% | $157.0M +64.2% | $95.6M | — | — | — |
| Operating Cash Flow | $33.3M +29.3% | $25.8M +156.4% | $-45.8M -296.5% | $-11.5M -162.5% | $18.5M -75.1% | $74.3M |
| Free Cash Flow | $-1.3M +85.9% | $-9.1M +91.6% | $-107.8M -210.7% | $-34.7M -5128.7% | $690.0K -98.8% | $58.8M |
Get alerted when OFIX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Orthofix Medical Inc. including:
Top Institutional Holders of OFIX
Engine Capital Management, LP
$41.8M4,575,675 shJuniper Investment Company, LLC
$40.6M4,442,543 shRubric Capital Management LP
$34.0M3,721,715 shBlackRock, Inc.
$30.4M3,326,560 shPARADIGM CAPITAL MANAGEMENT INC/NY
$30.2M3,300,499 shARMISTICE CAPITAL, LLC
$29.8M3,264,000 shVANGUARD CAPITAL MANAGEMENT LLC
$15.8M1,731,108 shGEODE CAPITAL MANAGEMENT, LLC
$9.6M1,048,081 shSTATE STREET CORP
$8.7M953,148 shAQR CAPITAL MANAGEMENT LLC
$8.1M887,282 sh
| Fund | Value | Shares |
|---|---|---|
| Engine Capital Management, LP | $41.8M | 4,575,675 |
| Juniper Investment Company, LLC | $40.6M | 4,442,543 |
| Rubric Capital Management LP | $34.0M | 3,721,715 |
| BlackRock, Inc. | $30.4M | 3,326,560 |
| PARADIGM CAPITAL MANAGEMENT INC/NY | $30.2M | 3,300,499 |
| ARMISTICE CAPITAL, LLC | $29.8M | 3,264,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.8M | 1,731,108 |
| GEODE CAPITAL MANAGEMENT, LLC | $9.6M | 1,048,081 |
| STATE STREET CORP | $8.7M | 953,148 |
| AQR CAPITAL MANAGEMENT LLC | $8.1M | 887,282 |
Companies Similar to OFIX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Inogen Inc
QuidelOrtho Corp
ARTIVION, INC.
Enovis CORP
ANGIODYNAMICS INC
RxSight, Inc.
MACROGENICS INC
NEOGEN CORP
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put OFIX on your watchlist
Track score changes the day Orthofix Medical Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OFIX a good stock to buy?
13F Pro's AI-powered analysis of Orthofix Medical Inc. (OFIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OFIX are available on the OFIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OFIX is classified as a small company.
Which hedge funds own OFIX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OFIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Orthofix Medical Inc.'s investment landscape.